Recent reports demonstrated that intratumoral injection of a phospholipid-conjugated TLR7 agonist increased the ratio of M1/M2 TAMs in several tumor models [24], and subcutaneous injection of resiquimod in CT26 tumors converted monocytic MDSCs into non-suppressive state [23]. Here, TLR7 is linked to neoplasm.